A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
ClinicalTrials.gov ID: NCT05278104
Sponsor: Boehringer Ingelheim
Information provided by: Boehringer Ingelheim (Responsible Party)
Last Update Posted: 2023-09-06
Brief Summary:
The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency, Perseverance, Premeditation, and Sensation Seeking-Positive Urgency Impulsive Behavior Scale (S-UPPS-P) Impulsive Behavior Scale. The secondary objective is to evaluate the safety of atomoxetine.
Official Title:
Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial to Evaluate the Effects of Atomoxetine on Impulsivity in Behavioral Laboratory Tasks in Adult ADHD Patients
Intervention / Treatment:
- Drug: Zentiva®
- Drug: Placebo
| Category | Value |
|---|---|
| Study Start (Actual) | 2023-05-17 |
| Primary Completion (Estimated) | 2024-02-12 |
| Study Completion (Estimated) | 2024-04-11 |
| Enrollment (Estimated) | 96 |
| Study Type | Interventional |
| Phase | Not Applicable |
| Other Study ID Numbers |
0352-2159 |